These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 18835519)

  • 1. Frequency of abnormal correlation between leptin and the body mass index during first and second generation antipsychotic drug treatment.
    Peña R; Marquina D; Serrano A; Elfakih Y; de Baptista EA; Carrizo E; Fernández V; Valery L; Teneud L; Baptista T
    Schizophr Res; 2008 Dec; 106(2-3):315-9. PubMed ID: 18835519
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Similar frequency of abnormal correlation between serum leptin levels and BMI before and after olanzapine treatment in schizophrenia.
    Baptista T; Dávila A; El Fakih Y; Uzcátegui E; Rangel NN; Olivares Y; Galeazzi T; Vargas D; Peña R; Marquina D; Villarroel V; Teneud L; Beaulieu S
    Int Clin Psychopharmacol; 2007 Jul; 22(4):205-11. PubMed ID: 17519643
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of clozapine and olanzapine on cytokine systems are closely linked to weight gain and drug-induced fever.
    Kluge M; Schuld A; Schacht A; Himmerich H; Dalal MA; Wehmeier PM; Hinze-Selch D; Kraus T; Dittmann RW; Pollmächer T
    Psychoneuroendocrinology; 2009 Jan; 34(1):118-28. PubMed ID: 18835660
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hormonal markers of metabolic dysregulation in patients with severe mental disorders after olanzapine treatment under real-life conditions.
    Birkenaes AB; Birkeland KI; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2009 Apr; 29(2):109-16. PubMed ID: 19512971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Coagulation and inflammation markers during atypical or typical antipsychotic treatment in schizophrenia patients and drug-free first-degree relatives.
    Carrizo E; Fernández V; Quintero J; Connell L; Rodríguez Z; Mosquera M; Acosta A; Baptista T
    Schizophr Res; 2008 Aug; 103(1-3):83-93. PubMed ID: 18436434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin and leptin levels in patients with schizophrenia or related psychoses--a comparison between different antipsychotic agents.
    Melkersson KI; Hulting AL
    Psychopharmacology (Berl); 2001 Mar; 154(2):205-12. PubMed ID: 11314683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The metabolic syndrome and its constituting variables in atypical antipsychotic-treated subjects: comparison with other drug treatments, drug-free psychiatric patients, first-degree relatives and the general population in Venezuela.
    Baptista T; Serrano A; Uzcátegui E; ElFakih Y; Rangel N; Carrizo E; Fernández V; Connell L; de Baptista EA; Quiroz S; Uzcátegui M; Rondón J; Matos Y; Uzcátegui L; Gómez R; Valery L; Novoa-Montero D
    Schizophr Res; 2011 Mar; 126(1-3):93-102. PubMed ID: 21071179
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Subjective and biological weight-related parameters in adolescents and young adults with schizophrenia spectrum disorder under clozapine or olanzapine treatment.
    Bachmann CJ; Gebhardt S; Lehr D; Haberhausen M; Kaiser C; Otto B; Theisen FM
    Z Kinder Jugendpsychiatr Psychother; 2012 May; 40(3):151-8; quiz 158-9. PubMed ID: 22532107
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early effects of olanzapine on serum levels of ghrelin, adiponectin and leptin in patients with schizophrenia.
    Hosojima H; Togo T; Odawara T; Hasegawa K; Miura S; Kato Y; Kanai A; Kase A; Uchikado H; Hirayasu Y
    J Psychopharmacol; 2006 Jan; 20(1):75-9. PubMed ID: 16204328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body weight and leptin plasma levels during treatment with antipsychotic drugs.
    Kraus T; Haack M; Schuld A; Hinze-Selch D; Kühn M; Uhr M; Pollmächer T
    Am J Psychiatry; 1999 Feb; 156(2):312-4. PubMed ID: 9989571
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions.
    Birkenaes AB; Birkeland KI; Engh JA; Faerden A; Jonsdottir H; Ringen PA; Friis S; Opjordsmoen S; Andreassen OA
    J Clin Psychopharmacol; 2008 Apr; 28(2):132-7. PubMed ID: 18344722
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential effects of olanzapine and clozapine on plasma levels of adipocytokines and total ghrelin.
    Lu ML; Wang TN; Lin TY; Shao WC; Chang SH; Chou JY; Ho YF; Liao YT; Chen VC
    Prog Neuropsychopharmacol Biol Psychiatry; 2015 Apr; 58():47-50. PubMed ID: 25496829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
    Gebhardt S; Haberhausen M; Heinzel-Gutenbrunner M; Gebhardt N; Remschmidt H; Krieg JC; Hebebrand J; Theisen FM
    J Psychiatr Res; 2009 Mar; 43(6):620-6. PubMed ID: 19110264
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clozapine and olanzapine are associated with food craving and binge eating: results from a randomized double-blind study.
    Kluge M; Schuld A; Himmerich H; Dalal M; Schacht A; Wehmeier PM; Hinze-Selch D; Kraus T; Dittmann RW; Pollmächer T
    J Clin Psychopharmacol; 2007 Dec; 27(6):662-6. PubMed ID: 18004133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma nitric oxide and leptin values in patients with olanzapine-induced weight gain.
    Atmaca M; Tezcan E; Ustundag B
    J Psychiatr Res; 2007; 41(1-2):74-9. PubMed ID: 16426639
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Betahistine effects on weight-related measures in patients treated with antipsychotic medications: a double-blind placebo-controlled study.
    Smith RC; Maayan L; Wu R; Youssef M; Jing Z; Sershen H; Szabo V; Meyers J; Jin H; Zhao J; Davis JM
    Psychopharmacology (Berl); 2018 Dec; 235(12):3545-3558. PubMed ID: 30382354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chronic clozapine treatment in female rats does not induce weight gain or metabolic abnormalities but enhances adiposity: implications for animal models of antipsychotic-induced weight gain.
    Cooper GD; Harrold JA; Halford JC; Goudie AJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2008 Feb; 32(2):428-36. PubMed ID: 17933447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Olanzapine increases plasma ghrelin level in patients with schizophrenia.
    Murashita M; Kusumi I; Inoue T; Takahashi Y; Hosoda H; Kangawa K; Koyama T
    Psychoneuroendocrinology; 2005 Jan; 30(1):106-10. PubMed ID: 15358448
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association between HTR2C and HTR2A polymorphisms and metabolic abnormalities in patients treated with olanzapine or clozapine.
    Gunes A; Melkersson KI; Scordo MG; Dahl ML
    J Clin Psychopharmacol; 2009 Feb; 29(1):65-8. PubMed ID: 19142110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metformin as an adjunctive treatment to control body weight and metabolic dysfunction during olanzapine administration: a multicentric, double-blind, placebo-controlled trial.
    Baptista T; Rangel N; Fernández V; Carrizo E; El Fakih Y; Uzcátegui E; Galeazzi T; Gutiérrez MA; Servigna M; Dávila A; Uzcátegui M; Serrano A; Connell L; Beaulieu S; de Baptista EA
    Schizophr Res; 2007 Jul; 93(1-3):99-108. PubMed ID: 17490862
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.